Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press34110.17650/1994-4098-2008-0-1-65-72GYNECOLOGY. NEW TECHNOLOGIESГИНЕКОЛОГИЯ. НОВЫЕ ТЕХНОЛОГИИEXPRESSION OF THE TUMOR-ASSOCIATED PROTEINS IN THE OVARIAN CANCERЭКСПРЕССИЯ ОПУХОЛЬАССОЦИИРОВАННЫХ БЕЛКОВ ПРИ РАКЕ ЯИЧНИКАBobrovaT. S.БоброваТ. С.
Russian Federation
ZhordaniaK. I.ЖорданиаК. И.
Russian Federation
ChuyevYu. V.ЧуевЮ. В.
Russian Federation
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences, MoscowГУ РОНЦ им. Н.Н. Блохина, РАМН, Москва150220081657215092014150920142008https://ojrs.abvpress.ru/ojrs/article/view/341

With the help of monoclonal antibodies (MCA-1, MCA-3, G1 class immunoglobulins) and polyspecific antiserum (As) by means of immunoblotting (IB) the increase of the expression of the tumor-associated proteins (TAP) in the samples of the tumor tissues (in 94, 55 and 38% respectively), metastatic lymph nodes — LN(m+) and sera of the patients with ovarian cancer (OC) (in 82, 77 and ~100% of the cases, respectively), was detected. The important feature of As was the reactivity with the samples of the LN (m+) on the numerous proteins (>5-10) in 78% of the patients. The statistical analysis of the data using Student t-criterion revealed the significant differences (MCA-1, MCA-3) in the expression of the markers in the tumor tissues and blood sera of the oncological patients compar- ing with the samples of the adjacent tissues, blood sera of the patients with the other tumor localization and healthy donors (p<0,05). The further research using a larger amount of the clinical material and development of the more precise quantitative immunoenzyme analysis to measure TAP, is needed. It is possible that detection of TAP using MCA-1 and As may serve a basis for the creation of the test-system for the immunodiagnostics of the OC and determination of the stage of the tumor process.

ЭКСПРЕССИЯ ОПУХОЛЬАССОЦИИРОВАННЫХ БЕЛКОВ ПРИ РАКЕ ЯИЧНИКА

1. Жорданиа К.И. Злокачественные эпителиальные опухоли яичника. Совр Онкол 2000;2(2):51—5.Жорданиа К.И. Злокачественные эпителиальные опухоли яичника. Совр Онкол 2000;2(2):51—5.2. Skates S.J., Horick N., Yu Y. et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combin- ing cancer antigen CA-125II, CA15-3, CA-72-4, and macrophage colony-stim- ulating factor using mixtures of multivari- ate normal distributions. J Clin Oncol 2004;22(20):4059—66.Skates S.J., Horick N., Yu Y. et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combin- ing cancer antigen CA-125II, CA15-3, CA-72-4, and macrophage colony-stim- ulating factor using mixtures of multivari- ate normal distributions. J Clin Oncol 2004;22(20):4059—66.3. Wong N.K., Easton R.L., Panico M. et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA-125. J Biol Chem 2003;278(31):28619—34.Wong N.K., Easton R.L., Panico M. et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA-125. J Biol Chem 2003;278(31):28619—34.4. Atack D.B., Nisker J.A., Allen H.H. et al. CA-125 surveillance and second-look laparotomy in ovarian carcinoma. Am J Obstet Gynecol 1986;154:287—9.Atack D.B., Nisker J.A., Allen H.H. et al. CA-125 surveillance and second-look laparotomy in ovarian carcinoma. Am J Obstet Gynecol 1986;154:287—9.5. Bast R.C., Boyer C.M., Olt G.J. Ovarian cancer. Biological and therapeu- tic challenges. London; 1991. p. 265—75.Bast R.C., Boyer C.M., Olt G.J. Ovarian cancer. Biological and therapeu- tic challenges. London; 1991. p. 265—75.6. Galietta A., Pizzi C., Pettinato G. et al. Differential TAG-72 epitope expression in breast cancer and lymph node metas- tases: a marker of a more aggressive phe- notype. Oncol Rep 2002;9(1):135—40.Galietta A., Pizzi C., Pettinato G. et al. Differential TAG-72 epitope expression in breast cancer and lymph node metas- tases: a marker of a more aggressive phe- notype. Oncol Rep 2002;9(1):135—40.7. Gonzalez V.A.M., Duro G.F., Fraile B.B. et al. Prognostic value of the glycoprotein TAG-72 in patients with gastric cancer. Int J Biol Markers 2001;16(2):121—5.Gonzalez V.A.M., Duro G.F., Fraile B.B. et al. Prognostic value of the glycoprotein TAG-72 in patients with gastric cancer. Int J Biol Markers 2001;16(2):121—5.8. Hellstrom I., Raycraft J., Hayden-Ledbetter M. et al. The HE4(WEDC2) protein is a biomarker for ovarian carci- noma. Cancer Res 2003;63:3695—700.Hellstrom I., Raycraft J., Hayden-Ledbetter M. et al. The HE4(WEDC2) protein is a biomarker for ovarian carci- noma. Cancer Res 2003;63:3695—700.9. Wiener J.R., Nakano K., Kruzelock R.P. et al. Decreased Src tyrosine kinase activ- ity inhibits malignant human ovarian cancer tumor growth in a nude model. Clin Cancer Res 1999;5(8):2164—70.Wiener J.R., Nakano K., Kruzelock R.P. et al. Decreased Src tyrosine kinase activ- ity inhibits malignant human ovarian cancer tumor growth in a nude model. Clin Cancer Res 1999;5(8):2164—70.10. Hakak Y., Martin G.S. Ubiquitin- dependent degradation of active Src. Curr Biol 1999;9(18):1039—42.Hakak Y., Martin G.S. Ubiquitin- dependent degradation of active Src. Curr Biol 1999;9(18):1039—42.11. Zhang Z., Bast R.C., Yu Y. et al. Three biomarkers identified from serum proteomic analysis for detection of early stage ovarian carcinoma. Cancer Res 2004;64(16):5882—90.Zhang Z., Bast R.C., Yu Y. et al. Three biomarkers identified from serum proteomic analysis for detection of early stage ovarian carcinoma. Cancer Res 2004;64(16):5882—90.12. Боброва Т.С., Чуев Ю.В., Морозов В.А. Иммунологические и биохимические характеристики се- мейства белков, ассоциированных с некоторыми карциномами человека. Вестн РОНЦ им. Н.Н. Блохина РАМН. 2001;(3):25—31.Боброва Т.С., Чуев Ю.В., Морозов В.А. Иммунологические и биохимические характеристики се- мейства белков, ассоциированных с некоторыми карциномами человека. Вестн РОНЦ им. Н.Н. Блохина РАМН. 2001;(3):25—31.13. Боброва Т.С. Семейство калликреиновых генов человека: биология и роль в развитии рака яичников и других заболеваний. Вестн РОНЦ им. Н.Н. Блохина РАМН 2006;17(4):3—11.Боброва Т.С. Семейство калликреиновых генов человека: биология и роль в развитии рака яичников и других заболеваний. Вестн РОНЦ им. Н.Н. Блохина РАМН 2006;17(4):3—11.14. Боброва Т.С., Морозов В.А., Чуев Ю.В., Жорданиа К.И. Семейство белков выявлено с помощью моноклональных антител 1F3-2D4 (IgG1-клас- са) в карциномах человека и их метастазах. Рус журн «СПИД, рак и общественное здоровье». 2007;11(1):78—9.Боброва Т.С., Морозов В.А., Чуев Ю.В., Жорданиа К.И. Семейство белков выявлено с помощью моноклональных антител 1F3-2D4 (IgG1-клас- са) в карциномах человека и их метастазах. Рус журн «СПИД, рак и общественное здоровье». 2007;11(1):78—9.15. Закс Л. Статистическое оценивание. Пер. с нем. В.Н. Варигина. М., Статистика; 1976. с. 129—53.Закс Л. Статистическое оценивание. Пер. с нем. В.Н. Варигина. М., Статистика; 1976. с. 129—53.16. Kapadia C., Ghosh M.C., Grass L., Diamandis E.P. Human kallikrein 13 involvement in extracellular matrix degradation. Biochem Biophys Res Commun 2004;323(3):1084—90.Kapadia C., Ghosh M.C., Grass L., Diamandis E.P. Human kallikrein 13 involvement in extracellular matrix degradation. Biochem Biophys Res Commun 2004;323(3):1084—90.17. Yousef G.M., Diamandis E.P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001;22:184—204.Yousef G.M., Diamandis E.P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001;22:184—204.18. Ghosh M.C., Grass L., Soosaipillai A. et al. Human kallikrein 6 degrades extra- cellular matrix proteins and may enhance the metastatic potential of tumor cells. Tumor Biol 2004;25(4):193—9.Ghosh M.C., Grass L., Soosaipillai A. et al. Human kallikrein 6 degrades extra- cellular matrix proteins and may enhance the metastatic potential of tumor cells. Tumor Biol 2004;25(4):193—9.19. Luo L., Katsaros D., Scorilas A. et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and progno- sis. Cancer Res 2003;63:807—11.Luo L., Katsaros D., Scorilas A. et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and progno- sis. Cancer Res 2003;63:807—11.20. Borgono C.A., Grass L., Soosaipillai A. et al. Human kallikrein 14. A new poten- tial biomarker for ovarian and breast can- cer. Cancer Res. 2003;63:9032—41.Borgono C.A., Grass L., Soosaipillai A. et al. Human kallikrein 14. A new poten- tial biomarker for ovarian and breast can- cer. Cancer Res. 2003;63:9032—41.21. Yousef G.M., Polymeris M.-E., Grass L. et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003;63:3958—65.Yousef G.M., Polymeris M.-E., Grass L. et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003;63:3958—65.